Phenotypic and Functional Characterization of Müller Glia Isolated from Induced Pluripotent Stem Cell-Derived Retinal Organoids: Improvement of Retinal Ganglion Cell Function upon Transplantation by Eastlake, K et al.
Phenotypic and Functional Characterization
of Müller Glia Isolated from Induced Pluripotent
Stem Cell-Derived Retinal Organoids: Improvement
of Retinal Ganglion Cell Function upon
Transplantation
KAREN EASTLAKE,a WEIXIN WANG,a HARI JAYARAM,a CELIA MURRAY-DUNNING,a
AMANDA J. F. CARR,a CONOR M. RAMSDEN,a ANTHONY VUGLER,a KATRINA GORE,b
NADINE CLEMO,b MARK STEWART,a PETE COFFEY,a PENG T. KHAW,a G. ASTRID LIMB a
Key Words. Stem cells • Induced pluripotent stem cell • Müller glia • Glaucoma • Regeneration
ABSTRACT
Glaucoma is one of the leading causes of blindness, and there is an ongoing need for new thera-
pies. Recent studies indicate that cell transplantation using Müller glia may be beneﬁcial, but
there is a need for novel sources of cells to provide therapeutic beneﬁt. In this study, we have
isolated Müller glia from retinal organoids formed by human induced pluripotent stem cells (hiP-
SCs) in vitro and have shown their ability to partially restore visual function in rats depleted of
retinal ganglion cells by NMDA. Based on the present results, we suggest that Müller glia derived
from retinal organoids formed by hiPSC may provide an attractive source of cells for human reti-
nal therapies, to prevent and treat vision loss caused by retinal degenerative conditions. STEM
CELLS TRANSLATIONAL MEDICINE 2019;00:1–10
SIGNIFICANCE STATEMENT
There is a need for novel therapies to treat retinal degenerative conditions such as glaucoma.
The authors suggest that Müller cells isolated from induced pluripotent stem cells (iPSCs)-
derived retinal organoids may constitute a well-traceable source of cells to develop such thera-
pies. The study shows that intravitreal transplantation of iPSC-derived Müller glia into an experi-
mental rat model of retinal ganglion cell depletion can partially restore visual function. This
response was judged by an improvement of the negative scotopic threshold response of the
electroretinogram. The results suggest that iPSC-derived Müller glia constitute an important
source of cells for human retinal therapies.
INTRODUCTION
Glaucoma is one of the leading causes of blind-
ness throughout the world [1]. It is character-
ized by high intraocular pressure, gradual loss
of retinal ganglion cells (RGCs) and optic nerve
damage [2, 3]. Current strategies to treat glau-
coma only slow progression of the disease, and
not all patients respond well to treatment,
leading to severe sight loss and visual disability.
Recent studies indicate that cell transplantation
therapies may be developed with the aim to
provide neurotrophic support to maintain the
viability and function of remaining neurons and
to potentially repair axonal damage.
Müller glia with stem cell characteristics
were ﬁrst identiﬁed in the zebraﬁsh [4], in
which they are responsible for the complete
regeneration of the adult retina after injury [5,
6]. In this species, Müller glia re-enter the cell
cycle to generate multipotent progenitors that
proliferate, migrate, and differentiate into most
neural cell types [7], that also restore retina
function [8]. Although complete retinal regener-
ation has not been observed in other species,
limited regenerative potential of Müller glia has
been observed in chick [9] and rodent [10, 11]
retinae. In rodent retina in vivo, it is reported
that Müller glia can re-enter the mitotic cycle to
generate amacrine cells in response to growth
factors [10] or photoreceptors in response to
N-methyl-D-aspartate (NMDA) [11]. A population
of Müller glia isolated from the adult human
retina has also been shown to have stem cell
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characteristics (human Müller stem cells [hMSC]) in vitro. These
cells, can be isolated from cadaveric donors, become spontane-
ously immortalized in vitro, and acquire markers and function of
retinal neurons after culture with various growth and differentiation
factors [12–14]. However, there is no evidence of regeneration
occurring after disease or injury in humans. That Müller glia may
have potential for therapeutic application in glaucoma derives from
experimental studies showing that hMSCs have the ability to par-
tially restore visual function in rodent and feline models of NMDA-
induced RGC damage [15, 16]. In addition, when directed toward a
photoreceptor fate, these cells were shown to improve rod function
in the P2H3 rat (a model of retinitis pigmentosa) after subretinal
transplantation [17]. Müller glia derived from cadaveric donors pre-
sent major difﬁculties for clinical application because of the risks of
disease transmission caused by prions and nonidentiﬁed patho-
gens, as well as limitations because of the histocompatibility
issues. Pluripotent stem cells, however, have the potential to
overcome these issues, and recent studies have shown that
retinal organoids that exhibit the characteristics of a whole
laminated neural retina can be generated by both human
induced pluripotent stem cells (hiPSC) and embryonic stem
cells (hESC) in vitro [18, 19]. Various sources of hESCs and hiP-
SCs that comply with regulatory requirements for human ther-
apies have become available and this will potentially facilitate
the derivation of cells for retinal therapies in the near future.
This study aimed to isolate Müller glia from retinal organoids
formed by hiPSC cells in vitro and to assess their ability to partially
restore visual function in rats depleted of RGC by NMDA. We
examined the purity and nature of the cells isolated from these
organoids by determining the gene and protein expression of
well-known markers of Müller glia. We also investigated the ability
of these cells to partially restore visual function upon transplanta-
tion into the vitreous of rats depleted of RGC as previously shown
with Müller glia isolated from adult human retina [15]. The out-
come of the transplantation was evaluated by assessing the nega-
tive scotopic threshold response (nSTR) of the electroretinogram
(ERG) and by immunohistochemical analysis of the transplanted
retina in vitro. Based on the present results, we propose that
Müller glia derived from retinal organoids formed by hiPSC may
provide an attractive source of cells for human retinal therapies,
to prevent and repair vision loss caused by retinal degenerative
conditions such as glaucoma.
MATERIALS AND METHODS
Stem Cell Maintenance and Retinal Organoid
Differentiation
The hiPSC line used in this study was created from BJ ﬁbro-
blasts (Stemgent, Glasgow, U.K. Cat. No. 08-0027) as previously
described by Carter et al. [20]. BJ iPSC cells were maintained
in TeSR-E8 (StemCell Technologies, Cambridge, U.K.) and grown
on Matrigel (Corning, St David’s Park, U.K.)-coated six-well
plates. Differentiation of human pluripotent stem cells into
retinal organoids was based on previous protocols developed
by Nakano et al. [18] and Parﬁtt et al. [21]. Upon conﬂuence,
cells were washed with ×1 phosphate-buffered saline (PBS)
and dissociated with TryplE (ThermoFisher, U.K.) containing
10 μM ROCKi (Y-27632, Millipore,Watford, U.K.) and 0.5 mg/ml
DNase (Sigma-Aldrich, U.K.) and pelleted. Cells were seeded to
a density of 9,000 cells per well in a v-bottomed 96-well plate
(PrimeSurface Sumilon low adhesion, Alpha Laboratories, U.K.) in
Glasgow Minimum Essential Medium (GMEM) with L-glutamine
containing 20% KOSR (ThermoFisher), 1% ×100 sodium pyruvate
(ThermoFisher, U.K.), 1% ×100 nonessential amino acids
(ThermoFisher), 1% ×100 penicillin/streptomycin (ThermoFisher,
U.K.), and 50 μM β-mercaptoethanol (ThermoFisher, U.K.) con-
taining 20 μM ROCKi and 3 μM Wnt antagonist (Millipore, Wat-
ford, U.K.). After 2 days in culture, wells were topped up with
100 μl of GMEM media containing 20% Knockout serum replace-
ment (KOSR), 1% ×100 sodium pyruvate, 1% ×100 nonessential
amino acids, 1% ×100 penicillin/streptomycin, 50 μM
β-mercaptoethanol, 20 μM ROCKi, 3 μM Wnt antagonist, and
2% Matrigel. Half media change was performed twice weekly.
On day 12, embryoid bodies (EBs) formed were transferred
into separate wells of a 25-well squared, low-adhesion plate,
and incubated in GMEM with L-glutamine, 20% KOSR, 10%
fetal calf serum (FCS) 1% ×100 sodium pyruvate, 1% ×100
nonessential amino acids, 1% ×100 penicillin/streptomycin,
and 50 μM β-mercaptoethanol containing 1% Matrigel and
100 nM smoothened agonist (SAG; Millipore, Watford, U.K.).
On day 15, the same media was replaced containing 1% Mat-
rigel and 100 nM SAG. On day 18, medium was replaced with
Dulbecco’s modiﬁed Eagle’s medium/F12-glutamax containing
10% FCS, 1% ×100 N2 supplement (ThermoFisher, U.K.; 1%
penicillin/streptomycin/amphotericin and 0.5 μM retinoic acid
[Sigma-Aldrich, U.K.]). EBs, from which retinal organoids become
visible between days 18 and 30, were then fed twice weekly.
From days 30 to 50, retinal organoids were cut from the EBs
under the microscope using microblades and placed into new
25 square low-adhesion plates. This was to ensure that only neu-
ral retinal tissue remained and matured in culture. Before disso-
ciation, any pigmented cell, occasionally forming with the
organoids, was removed to prevent any possible retinal pigment
epithelial contamination in the growing cultures. For long term,
culture medium was replaced twice weekly (illustrated in Fig. 1A).
All cells were maintained at 37C, 5% CO2, and atmospheric O2.
Isolation of Müller Glia from Retinal Organoids
Müller cells were harvested from retinal organoids between
30 and 281 days after initiation of retinal differentiation for char-
acterization analysis. Cells used for intravitreal transplantations
were derived from organoids at day 281. Organoids were dissoci-
ated using a papain dissociation kit protocol supplied by the
manufacturer (Worthington Biochemical, Lakewood, NJ, USA).
Brieﬂy, retinal organoids were incubated with papain for approx-
imately 10-15 minutes at 37C with agitation by pipetting every
5 minutes. Pelleted cell suspensions were then plated as
described previously for Müller glia isolated from human cadav-
eric retina (illustrated in Fig. 1B).
Immunohistochemistry of Retinal Organoids and
Isolated Cells
Cells were grown to a conﬂuent monolayer on ﬁbronectin-coated
glass coverslips and washed in PBS before ﬁxation in 4% parafor-
maldehyde for 5 minutes. After ﬁxation, cells were cryoprotected
in 30% sucrose for 30 minutes and allowed to dry before freez-
ing. For use, cells were defrosted and 500 μl of tris-buffered
saline (TBS) + 0.3% triton X was added to the cells. Cells were
blocked for 1 hour in TBS + 0.3% triton + 5% donkey serum
before the addition of the primary antibody (diluted in blocking
buffer). Primary antibodies (see Supporting Information Table S1)
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were incubated overnight at 4C. Cells were then washed with
TBS three times for 5 minutes. Secondary antibodies (Alexa
ﬂour, Invitrogen, U.K. 1:500 in TBS + 0.3% triton) were incu-
bated for 3 hours at room temperature in the dark. Slides were
then washed in TBS and coverslips mounted with Fluoroshield
Mounting Medium containing 40,6-diamidino-2-phenylindole
(DAPI; Abcam, Cambridge, U.K.), sealing with nail varnish.
Flow Cytometry Analysis
Cells were detached from tissue culture ﬂasks to obtain a sin-
gle cell suspension. These were then washed in PBS to remove
any remaining tissue culture medium. Cells were then incu-
bated with primary antibodies to CD29, CD44 (positive con-
trols), SSEA4, and cytokeratin-18 (negative control markers)
for 30 minutes in the dark. The cells were then washed 3 times
by centrifugation and resuspended in sterile PBS. Corresponding
isotype controls and a no primary antibody cell suspension were
used as negative controls (see Supporting Information Table S1).
Fluorescence-activated cell sorting (FACS) analysis was performed
using a The BD LSRFortessa X-20 cell analyzer (BD Biosciences,
Berkshire, U.K.). Supporting Information Fig. S1 shows data for
negative markers SSEA4 and cytokeratin-18, and Supporting Infor-
mation Fig. S2 shows ﬂow cytometry data for all isotype controls.
Gene Expression Analysis by Reverse
Transcription-Polymerase Chain Reaction
Total cellular RNA was isolated from cell pellets using the RNeasy
system (Qiagen, Hilden, Germany; http://www.qiagen.com). For
each reverse transcription reaction, 1 μg of total RNA was
reverse transcribed in 20-μl reactions by adding 1 μl of oligo
d(T)12-18 primers (Invitrogen) and 1 μl dNTP (Promega) to each
sample and incubated for 5 minutes at 65C in a thermal cycler
before adding 4 μl of ﬁrst strand buffer (Invitrogen), 1 μl 0.1 M
DTT, 0.5 μl Rnase inhibitor (RNasin Plus, N2611, Promega, U.K.),
and 1 μl Superscript IV (Invitrogen) and incubating in the ther-
mal cycler for a further 10 minutes at 55C and 10 minutes at
80C. Polymerase chain reaction (PCR) ampliﬁcation was per-
formed in 20-μl volume by addition of 10 μl of GoTaq Green
master mix (Cat. No. M712; Promega, U.K.), which contains a
mix Taq DNA polymerase, dNTPs, MgCl2, and reaction buffers
and was used along with 7 μl RNase free water, 1 μl of each for-
ward and reverse primers, and 1 μl cDNA. The mixture was
incubated at 94C for 5 minutes, followed by an appropriate
number of cycles as follows: 94C for 1 minute, annealing tem-
perature C for 1 minute, 72C for 1 minute; and one cycle of
72C for 5 minutes. PCR products were analyzed by agarose gel
electrophoresis (2%) containing gel red (Supporting Information
Table S2) for primer sequences.
Animal Husbandry, Tolerization, Immunosuppression,
and Anesthesia
Wild-type Lister hooded rats were maintained according to the
U.K. Home Ofﬁce regulations for the care and use of laboratory
animals (Scientiﬁc Procedures Act 1986). The use of the animal
species for the study was approved by the local ethics commit-
tee at University College London, Institute of Ophthalmology
Figure 1. Schematic summary representation of the methods used in retinal organoid differentiation and Müller glia isolation for trans-
plantation. (A): Formation of retinal organoids from induced pluripotent stem cells, from embryoid body formation to isolation of the
growing retina. (B): Retinal organoids were dissociated using papain to obtain a single cell suspension. (C): Isolated Müller glia from reti-
nal organoids were grown into conﬂuent monolayers before harvest for intravitreal injection into the rat eye.
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and the U.K. Home Ofﬁce. The animals were given access to
food and water ad libitum and kept under 12-hour light/12-hour
dark cycles. All animals used in the study were tolerized within
24 hours of birth by an intraperitoneal injection of 1 × 105
Müller glia derived from iPSC retinal organoids using protocols
described previously [15]. Anesthetic for intravitreal transplanta-
tion procedures consisted of ketamine (60 mg/kg) and xylazine
(7.5 mg/kg). Immunosuppression, started 2 days before cell
transplantations, was administered daily in drinking water, and
consisted of 25 mg azathioprine, 5 mg prednisolone, and 210 mg
cyclosporin per liter.
Induction of RGC Damage by NMDA and Intravitreal
Müller Cell Transplantation
Four-week-old animals were anesthetized and pupils treated
with tropicamide (1% w/v, Minims; Bausch and Lomb, Kingston-
upon-Thames, Surrey, U.K.), phenylephrine hydrochloride (2.5%
w/v, Minims; Bausch and Lomb, Kingston-upon-Thames, Surrey,
U.K.), and oxybuprocaine hydrochloride (0.4% w/v; Minims
Bausch and Lomb, Kingston-upon-Thames, Surrey, U.K.) drops.
Viscotears (Bausch and Lomb, Kingston-upon-Thames, Surrey,
U.K.) were used to make sure the fellow eye did not dry out
during the procedure. Injections were performed using a 5 μl
Hamilton syringe and 32G needle. RGC damage was induced by
injection of 2 μl of a mixture of NMDA (80 μM) and triamcino-
lone (80 mg/ml) into the intravitreal space of the left eye. To
allow for assessment of RGC damage at 1 week after NMDA
injection (Supporting Information Fig. S3), we performed ERG
analysis at this time point. To comply with U.K. Home Ofﬁce reg-
ulations and to allow for anesthetic recovery from the ERG test,
cells were transplanted a week after the ﬁrst ERG test. Animals
were injected with 2 μl of a cell suspension consisting of 1 μl
chondroitinase ABC and 1 μl of cells into the same eye (illus-
trated in Fig. 1C). Because Müller cells were frozen in small num-
bers upon isolation from the organoids, to obtain sufﬁcient
number of Müller glia for transplantation and characterization,
we expanded these cells over a period of 2 weeks before injec-
tion. Three different injections were given to each of three
experimental groups (n = 16 for each group) as follows—group
A: medium-no cells (sham); group B: 4 × 104 Müller glial cells
derived from hiPSC retinal organoids; and group C: 1 × 105 cells
Müller glial cells derived from hiPSC retinal organoids. Four weeks
after transplantation, animals were assessed for their RGC function
by dark adapted ERGs and subsequently euthanized by terminal
anesthesia, followed by paraformaldehyde (4%) perfusion.
Scotopic ERG Recordings
Animals were dark adapted overnight before ERGs. Rats were
anesthetized as described above, and both eyes treated with
tropicamide (1% w/v) and phenylephrine hydrochloride (2.5% w/v)
to dilate the pupils and oxybuprocaine hydrochloride (0.4% w/v) to
anesthetize. Viscotears were used to ensure the cornea remained
hydrated. Animals were housed in a Faraday cage for ERG record-
ings and placed on a heated table to control the body tempera-
ture, in a Ganzfeld stimulator (Colordome; Diagnosys, Cambridge,
U.K.; http://diagnosysllc.com). Flash stimuli (4-millisecond dura-
tion, repetition rate of 0.13 Hz) were presented in the Ganzfeld
color dome by light-emitting diode stimulator at intensities of −6.5
to −2 log cd second/m2. The ﬂash stimulus was repeated 30 times
for each light intensity. The responses were measured using the
Espion Diagnosys V6 software. Measurements for nSTR analysis
were analyzed by determination and recording of the maximal
negative response in the range of 160–230 milliseconds (for nSTR)
at each light intensity.
All ERG analyses were performed on R version 3.4.0 (The R
Foundation for Statistical Computing) using the R program
“Analyse summary statistics R.” An analysis of variance model
was ﬁtted to each intensity in turn. That model investigated
effects of day and treatment group. The equivalent ERG sum-
mary post-NMDA was considered as a potential covariate but
no relationship was observed (p > .10), so the summary was
not included in the model. Least square (LS) means were
obtained for each treatment group, and differences in mean
response to the control group were presented together with
corresponding 95% conﬁdence intervals (CI). As an additional
exploration, a mixed effects model was ﬁtted to data for inten-
sities −4.5 to −3 combined. The ﬁxed effects included in the
model were day, intensity, treatment, and treatment by inten-
sity interaction. Animal was ﬁtted as a random effect. The LS
means were obtained as an averaged for each treatment
across the intensities used in the test, and differences in aver-
age response to the control group were presented, together
with 95% CI. The assumptions of all models were assessed
visually using diagnostic plots.
Immunocytochemistry and Confocal Microscopy for
Visualizing Transplanted Cells
After perfusion ﬁxation, eyes were enucleated and placed in 4%
paraformaldehyde overnight before replacing with 30% sucrose
for cryopreservation. The lens was then removed from each eye
and the remaining orbit embedded in OCT before sectioning at
16 μM using a Leica cryostat and mounting on Superfrost plus
slides (VWR, U.K.). Sections were washed with TBS and blocked at
room temperature with TBS containing 0.3% triton and 5% don-
key serum for 1 hour. To identify the transplanted human Müller
glia in the rat eyes, mouse monoclonal antibodies to human CD29
(1:300; Santa Cruz Biotechnology, U.S.A) and human Nestin (1:300;
Millipore, Watford, U.K.) were used in conjunction. Primary anti-
bodies were diluted in blocking buffer and incubated overnight at
4C. Slides were then washed 3 times in TBS, and both primary
antibodies were probed with the secondary antibody Alexa ﬂuor
488 (Invitrogen, U.K.) (1:500; 3 hours; Thermo Fischer, U.K.). Slides
were washed in TBS 3 times before addition of a mounting media
containing DAPI, covered with a glass coverslip, and sealed with nail
varnish for microscope examination. Immunoﬂuorescence staining
was captured using a Leica 710 confocal microscope.
RESULTS
Müller Glia Development Within Retinal Organoids
Two days after initiation of the differentiation process, hiPSCs
formed cellular spheroids characteristic of EBs. These EBs con-
tinued to enlarge, and by day 12, small cell protrusions were
seen emerging from these structures. After 18 days, these pro-
trusions were observed expanding on the periphery of the EBs
to form nearly transparent cell structures, which denote reti-
nal development. Between days 20 and 35, these retinal struc-
tures were sectioned from the EB and transferred to new
plates to allow maturation for up to 300 days. During this
period, retinal laminations could be increasingly observed by
phase contrast microscopy (Fig. 2A). Immunocytochemical
© 2019 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
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staining of these organoids showed that after 90 days from ini-
tiation of the retinal differentiation process, Müller glia markers
including Nestin, vimentin, glutamine synthetase, Chx10, and
Cellular retinaldehyde binding protein (CRALBP) were expressed
in cells that extend across the whole width of the retinal struc-
ture, which is one of the main features of Müller glia in the
mature mammalian retina in vivo (Fig. 2B).
Characterization of Müller Glia Isolated from Retinal
Organoids Formed by iPSC
After dissociation of retinal organoids, cells were plated on
ﬁbronectin-coated culture plates. Initially they formed small
cell clusters (Fig. 3Ai) and after a few days in culture, many of
these cell groups form neurosphere-like structures, which is
often observed with Müller glia isolated from the adult human
retina [13] (Fig. 3Aii). Cells were expanded in the presence of
Epidermal growth factor (EGF) and Basic ﬁbroblast growth fac-
tor (bFGF), and after 4–6 weeks culture, they were examined
Figure 2. Retinal organoid development and Müller glia identiﬁ-
cation. (A): Representative phase microscopy images of retinal
organoid development from induced pluripotent stem cells from
days 2 to 300. (B): Confocal microscopy images of a retinal
organoid at day 99 after initiation of differentiation, showing
expression of the Müller glia-speciﬁc markers CRALBP, nestin,
vimentin, Chx10, and glutamine synthetase. Scale bar = 20 μm.
Figure 3. Morphology and expression proﬁle of Müller glia iso-
lated from induced pluripotent stem cell-derived retinal organoids.
(A): (i) Appearance of Müller glia after 1 day in culture
(ii) characteristic formation of sphere-like structures at early pas-
sages. (iii) Muller glia grown in the presence of EGF alone display
typical bipolar morphology and adhesion to culture plates.
(iv) Müller glia cultured in the presence of EGF and FGF show fast
growth and division as indicated by the presence of phase bright
nuclei, characteristic of dividing cells. Scale bar = 100 μm. (B): Gel
bands represent the expression of mRNA coding for Müller glia
and progenitor factors in cells isolated from retinal organoids at
different times after initiation of retinal differentiation. Duplicate
bands represent two consecutive passages of the same cell
preparation.
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for gene and protein expression of Müller glial cell markers. We
observed that bFGF greatly increased expansion rate of the cell
colonies but was not necessary for continued expansion after
the ﬁrst three passages (Fig. 3Aiii–iv). Proliferating cells showed
a characteristic Müller glia bipolar-like morphology with membrane
protrusions, characteristic of Müller glia. This morphology was
maintained throughout several passages. If cells were maintained
in the presence of FGF for a long term, a morphology characteristic
of neurosphere-like forming cells with shorter processes and phase
bright nuclei was often observed (Fig. 3Aiv).
Cells isolated from retinal organoids at 34, 70, 90, 219, and
281 days after initiation of organoid differentiation were exam-
ined for the expression of genes coding for Müller glia and neural
progenitor markers, the characteristics of adult human Müller glia
[13]. Expression of mRNA coding for the Müller glia markers
CRALBP, glutamine synthetase, nestin, and vimentin was observed
in two different passages of all cell preparations (Fig. 3B). In addi-
tion, the expression of mRNA coding for the progenitor markers
Sox9, Pax6, and notch1 was also observed in two different pas-
sages of all cell preparations (Fig. 3B).
Figure 4. Protein expression proﬁle of Muller glia isolated from induced pluripotent stem cell-derived retinal organoids. (A): Flow cyto-
metry analysis of Muller glia isolated from retinal organoids showing double positive staining for CD44 and CD29 by the majority of cells
(>99.7%). (B): Immunoﬂuorescence staining of isolated Müller glia cells showing expression of CD29, vimentin, CRALBP, glutamine synthe-
tase, nestin, CD44, and Sox9, characteristic markers of Müller glia. Scale bar = 50 μm. Abbreviation: DAPI, 40,6-diamidino-2-phenylindole.
© 2019 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
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Purity of the Müller Cell Preparation Obtained from
Retinal Organoids
Cells isolated from retinal organoids were expanded on
ﬁbronectin-coated culture plates to obtain sufﬁcient number for
characterization studies. As determined by ﬂow cytometry
(FACS) analysis, the proportion of cells coexpressing the Müller
cell surface markers CD44 and CD29 was above 99.7% (Fig. 4A).
To conﬁrm speciﬁcity, the cell preparations were also examined
for the expression of negative markers including SSEA4, a known
stem cell marker and cytokeratin-18, an epithelial cell marker.
Both markers were shown to be under 1% positive for our
Müller glia cell preparation (Supporting Information Fig. S1).
Immunoﬂuorescence staining conﬁrmed the expression of pro-
genitor and Müller glia markers by the isolated retinal cells.
Costaining for the cell surface marker CD29 and the intermedi-
ate ﬁlament protein vimentin showed that all cells were
expressing both markers. Well-known Müller glia markers includ-
ing CRALBP and glutamine synthetase also showed prominent
cytoplasmic staining in the majority of the cells (Fig. 4B). Immu-
nostaining for the Müller glia cell surface marker CD44 was also
observed in all the cells, with a large proportion also staining for
nestin (Fig. 4B). In addition, nuclear staining for the Muller pro-
genitor marker Sox9 was observed in all cells (Fig. 4B).
Intravitreal Transplantation of hiPSC Derived Müller
Glia Partially Restores RGC Function in a Rat Model of
RGC Depletion
Intravitreal cell transplantation was performed as previously
described [15] following 2 weeks after intravitreal injection of
Figure 6. Localization of transplanted cells following immuno-
staining or retinal sections with antibodies to both human nestin
plus CD29 and Alexa ﬂour 488 used as a single secondary anti-
body. Images show eyes transplanted with (A) 1 × 105 cells and
(B) 4 × 104 cells. White arrows indicate the location of the cells.
Scale = 50 μm. Abbreviations: INL, inner nuclear layer; ONL, outer
nuclear layer; RGC, retinal ganglion cell layer.
Figure 5. Electroretinogram (ERG) responses after cell transplanta-
tion in the NMDA damaged rat eye. (A): Differences in 95% CI of
nSTR peak responses (measured between 160 and 230 millisecond)
between human Müller glia and sham (medium only) treatments
across all light intensities examined. (B): Comparison of the effects
of human Müller glial cell transplantation with control treatment
on the nSTR amplitude at 4 weeks postinjection across light intensi-
ties from −4.5 to −3 log cd second/m2 (n = 16 for each experimen-
tal group). (C): Scotopic ERG traces at −3 log to −6.5 log cd
second/m−2 showing responses to medium (sham control, green
lines), 1 × 105 cells (blue lines) and 4 × 104 cells (orange lines).
Arrows indicate emerging b-wave and nSTR. Abbreviations: CI, con-
ﬁdence interval; nSTR, negative scotopic threshold response.
www.StemCellsTM.com © 2019 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
Wiley Periodicals, Inc. on behalf of AlphaMed Press
Eastlake, Wang, Jayaram et al. 7
NMDA to cause RGC damage. Sixteen animals were used in
each of three experimental groups, receiving either a sham
injection (medium alone), 4 × 104 cells or 1 × 105 cells. To
assess RGC function, scotopic ERGs were performed 4 weeks
after cell transplantation to examine the nSTR, which denotes
RGC function. Using 95% CI and compared with control treat-
ment, statistical analysis of the effects of human Müller glia
cell injection showed an increase in the amplitude of the nSTR
across a range of relevant light intensities, with signiﬁcant dif-
ference (p < .05) being demonstrated with 1 × 105 human
Müller glia cells at a light intensity of −3.5 log cd second/m2
(Fig. 5A). Furthermore, statistical analysis of the data obtained
from eyes injected with both 4 × 104 and 1 × 105 iPSC-derived
human Müller glial cells when compared with control treat-
ment demonstrated a dose response and signiﬁcant improve-
ment (p = .038) in the nSTR across light intensities ranging
from −3.0 to −4.5 log cd second/m2 (Fig. 5B). Control animals
which received NMDA treatment but no cell transplantation
exhibited reduced nSTR and larger b-waves for luminance −4
through to −3.0 log cd second/m−2 in comparison to animals
receiving cell transplantations (Fig. 5C, arrows).
Antibodies to human CD29 and Nestin were used to
locate the transplanted human cells in the rodent eye. Immu-
nohistochemical staining of retinal sections from eyes
transplanted with 1 × 105 cells showed that cells were pre-
sent in 13 out of the 16 eyes transplanted. Cells with healthy
appearance were observed mostly in the vitreous (11 of 13),
and although no integration of the transplanted Müller glia
into the retina was observed, cells could be clearly seen
strongly attached to the RGC layer in three cases (Fig. 6A,
white arrow). In addition, transplanted cells were observed
attached to the lens in two cases (not shown). Overall, fewer
cells were observed in histological sections form eyes
transplanted with 4 × 104 cells as compared with those
receiving the higher dose (illustrated on left image of Fig. 6B).
In some cases, cell aggregates could be seen in the vitreous
(illustrated on right image of Fig. 6B).
DISCUSSION
In this study, we have used human iPSC to produce retinal
organoids for isolation and propagation of Müller glia in vitro.
Müller cells isolated from the organoids were then used for
transplantation into a rat model of RGC depletion by NMDA.
Results presented in this study indicate that Müller glia that
express CRALBP emerge at around day 90 after induction of
differentiation of iPSC into retinal organoids. These observa-
tions are comparable to other studies that have reported
expression of CRALBP in retinal organoids at similar stages of
organoid formation [19]. Upon transplantation, these cells par-
tially restored RGC function in the NMDA-damaged rat retina.
These observations suggest that retinal organoids derived from
iPSCs constitute an attractive source of Müller glia for cell
transplantation therapies to treat retinal degenerative condi-
tions. Therefore, we propose that Müller cells derived from
organoids produced by pluripotent cells in vitro may be poten-
tially used as a reliable and traceable source of cells for use in
retinal therapies.
The data showed that Müller glia isolated from retinal
organoids can be expanded over several passages and that their
proﬁle is comparable to published Müller cell lines derived from
human cadaveric donors, including the established human MIO-
M1 Müller cell line [12, 13]. Based on our previous studies, we
have characterized these cells by their morphology as well as
their gene and protein expression proﬁles which are distinctive
of Müller glia. Isolated cells exhibited bipolar morphology and
showed the ability to form sphere-like structures that have
been previously observed in the establishment of other Müller
glia cell lines when cultured in the presence of FGF2 [13]. Cells
isolated from the organoids expressed mRNA and protein cod-
ing for well-known Müller glia markers including glutamine syn-
thetase, CRALBP, nestin, and vimentin. The method of isolation
is simple and exploited on the expression of CD29, a β1
integrin, by Müller glia, whose main ligand is ﬁbronectin [22].
Hence, adherence of Müller glia to ﬁbronectin-coated plates
selectively promoted the emergence of highly pure populations
of Müller glia (>97%) as determined by FACS analysis of the
CD29 positive cell population, avoiding the need for further
puriﬁcation. This constitutes a simple method for selection and
puriﬁcation of Müller glia for regulatory compliance in the event
that these cells can be used for cell therapies. It is also well
documented that retinal neurons do not survive well in culture
without speciﬁc on-going support from extracellular signals [23],
suggesting that only glia are likely to survive and proliferate in
culture under the conditions used.
We also investigated the ability of Müller glia isolated
from retinal organoids formed by iPSC to restore RGC func-
tion in rats depleted of RGC by NMDA as previously shown in
our laboratory [15]. This model mimics the pathological fea-
tures of RGC damage observed in glaucoma and is a reliable
model of RGC damage which can be easily assessed by mea-
suring the nSTR response of the ERG [15]. Following NMDA
damage, we observed a reduction in the nSTR and a slight
elevation in the b-wave of the ERG, which is characteristic of
similar glaucoma models [24]. We observed a partial but sig-
niﬁcant restoration of the nSTR after transplantation of the
highest dose of cells used (1 × 105). Although injection of a
smaller number of cells (4 × 104) also resulted in an improve-
ment in the nSTR, this response was not signiﬁcant, indicating
the need for a suitable number of cells for transplantation to
improve retinal function. As with previous experimental models,
we observed cell aggregates in a small number of animals
(Fig. 6). However, we do not know whether this effect could
interfere with visual function. We could speculate that because
ﬂoaters present in human vitreous do not obstruct visual acuity,
small cell aggregates may not interfere with vision. However,
further studies are needed to assess the impact of these cell
aggregates before any translation into the clinic.
CONCLUSION
Results shown in this study are in agreement with previous
ﬁndings from our laboratory, where we showed therapeutic
beneﬁt of the transplanted human Müller glia cell line MIO-
M1 in this rat model of glaucoma-like damage [15]. As previ-
ously observed in the Lister hooded rat and feline models of
RGC depletion by NMDA [15, 16], cell integration into the
retina was not observed, yet the RGC function was partially
restored. Several studies have shown that RGC depletion
occurs after NMDA injection, which at present requires
© 2019 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by
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ex vivo examination of the retinal tissue and prevents the
assessment of transplantation in the same animal. Therefore,
we undertook functional analysis by means of ERGs to assess
RGC damage and the actual recovery of function in the
NMDA-treated animals. This also minimized the number of
animals used for the study. Studies by Goldberg and collabo-
rators have shown that if the soma of the RGC is still intact,
the cell recovers function in response to neurotrophic fac-
tors, but if it is damaged, they will not be repaired by these
factors [25]. This is the mechanism by which we are propos-
ing that Müller cells improve RGC function upon intravitreal
transplantation.
Together the results show that Müller glia derived from
pluripotent stem cells possess similar phenotypic characteris-
tics and ability to partially restore visual function in NMDA
depleted retina as Müller derived from the adult human ret-
ina. On this basis, it can be suggested that iPSC-derived Müller
glia may constitute a valuable resource for transplantation
studies that could be potentially translated into the clinic.
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